SCHEMBL1362387

SCHEMBL1362387

CC(=O)Nc1cccc(Nc2nccc(-c3c(-c4cccc(NC(=O)Cc5ccccc5Cl)c4)nc4sccn34)n2)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 15/20 0.71
KDR P35968 9/20 0.71
CSF1R P07333 6/20 0.71
PTK2 Q05397 4/20 0.71
EGFR P00533 14/20 0.69
ERBB2 P04626 14/20 0.69
CDK19 Q9BWU1 1/20 0.66
RET P07949 7/20 0.65
STK3 Q13188 7/20 0.65
MAP4K5 Q9Y4K4 7/20 0.65
MAP4K2 Q12851 6/20 0.65
FLT1 P17948 5/20 0.65
LCK P06239 7/20 0.63
MAP4K4 O95819 6/20 0.62
TAOK1 Q7L7X3 6/20 0.62
FYN P06241 5/20 0.62
PRKD3 O94806 4/20 0.62
AURKB Q96GD4 4/20 0.62
FGFR1 P11362 4/20 0.62
MINK1 Q8N4C8 4/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1364312 0.90 IGF1R (0.80) IGF1RKDRCSF1RPTK2EGFR
SCHEMBL1361436 0.87 KDR (0.71) IGF1RKDRCSF1RPTK2EGFR
SCHEMBL1364330 0.87 IGF1R (0.71) IGF1RKDRCSF1RPTK2EGFR
SCHEMBL1363248 0.87 IGF1R (0.83) IGF1RKDRCSF1RPTK2EGFR
SCHEMBL1361668 0.86 IGF1R (0.69) IGF1RKDRCSF1RPTK2EGFR
SCHEMBL1362650 0.86 IGF1R (0.67) IGF1RKDRCSF1RPTK2EGFR
SCHEMBL1363540 0.86 EGFR (0.82) IGF1RKDRCSF1RPTK2EGFR
SCHEMBL1362991 0.86 IGF1R (0.83) IGF1RKDRCSF1RPTK2EGFR
SCHEMBL1363383 0.86 EGFR (0.73) IGF1RKDRCSF1RPTK2EGFR
SCHEMBL1361734 0.85 IGF1R (0.83) IGF1RKDRCSF1RPTK2EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067409-B2 Protein kinase inhibitors ABBOTT LABORATORIES (US) 2011-11-29 US claimed
US-8067409-B2 Protein kinase inhibitors ABBOTT LABORATORIES (US) 2011-11-29 US disclosed
EP-2222682-A1 IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS Abbott Laboratories (US) 2010-09-01 EP disclosed
US-20090253723-A1 PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-10-08 US disclosed
WO-2009070516-A1 IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253723-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 IGF1R 1941/4885KDR 1617/4885CSF1R 4013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.